Monday, November 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· April 16, 2026

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

View original at finance.yahoo.com
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 -JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic…
Opening lines of the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JANX007 has shown a favorable safety profile with no Grade 3 cytokine release syndrome observed at clinically relevant dose levels using the current CRS mitigation strategy

    60% confidence
  • We are building a prostate cancer portfolio designed to address patients across multiple stages of disease, including both single and combination approaches

    60% confidence
  • JANX007 remains our lead prostate program, and we believe it has established a strong clinical foundation for PSMA-directed TRACTr therapy

    60% confidence
  • Janux's tumor-activated technology allows us to evaluate multiple molecular designs against the same validated target

    60% confidence
  • Early clinical data from JANX007 have demonstrated what Janux believes is potentially a best-in-class clinical profile in mCRPC

    60% confidence

Cited in these Via News reports